How do patent rights affect regulatory approvals and data exclusivity rights for pharmaceuticals in the EU?
This article sheds light on the relationship, or rather, absence of a relationship, between patent rights and regulatory approval procedures in the EU. The principle of 'patent linkage' has long been recognized and applied by regulatory authorities in the USA. The European Commission, however, opposes the idea of linking patent rights to marketing authorizations and pricing and reimbursement decisions. This position is grounded in Article 126 of Directive 2001/83 and is expected not to change anytime soon, given the clear reaffirmation thereof in the recent Sector Inquiry Report and Transparency Directive Proposal. Therefore, the European Medicines Agency or national authorities are not permitted to refuse approval and, likely, pricing and reimbursement of a generic when the innovative reference product is still protected by a patent. The authors, however, advocate that there are strong legal arguments for patent holders to challenge regulatory decisions that did not respect their patent rights before the competent national courts.
Covington & Burling LLP, Kunstlaan 44 Avenue des Arts, B - 1040, Brussel/Bruxelles.
Peter
P
Bogaert
Eveline
E
Van Keymeulen
D017277:Drug Approval; D005062:European Union; D010330:Patents as Topic; D004364:Pharmaceutical Preparations
D004364:Pharmaceutical Preparations